2026-10-29 22:07:39 UTC#541365newconfirmednews
WVE stock news
WVE stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-28 12:43:16 UTC#528817newconfirmednews
Oppenheimer maintains Outperform rating on Wave Life Sciences, sets $29 price target
tradingviewimportance 0.40trust 0.70Oppenheimer & Co. Inc. +0.30Wave Life Sciences Ltd. +0.50WVE-006 +0.40+1 entities
2026-10-27 19:20:00 UTC#523592newconfirmednews
Wave Life Sciences average analyst price target lowered to $18.02 from $18.42, consensus Buy rating maintained
2026-10-27 18:42:26 UTC#523449updateconfirmednews
Wave Life Sciences to initiate post-incretin maintenance trial in Q4 2026
2026-10-27 15:32:20 UTC#522437updateconfirmednews
Wave Life Sciences details WVE-007 Phase II-A, WVE-006 registration plan and GSK siRNA candidate progress
2026-10-27 13:32:30 UTC#521648duplicateconfirmednews
Wave Life Sciences reports Q3 2026 adjusted loss of $0.30 per share and revenue of $13.16 million
2026-10-27 12:27:05 UTC#521147newconfirmednews
Wave Life Sciences Q3 2026 earnings call begins
2026-10-27 11:55:47 UTC#520967newconfirmednews
Wave Life Sciences Q3 revenue $13.2M, net loss $61.9M; cash runway extended to Q3 2028
2026-10-27 11:33:36 UTC#520760newconfirmeddata release
Wave Life Sciences Q3 2026 GAAP EPS -$0.30 beats by $0.03, Revenue $13.16M beats by $8.77M
2026-10-26 15:16:38 UTC#515635newconfirmednews
Wave Life Sciences Ltd. Q3 2026 Earnings Preview
2026-10-01 12:15:00 UTC#398511duplicateconfirmednews
Wave Life Sciences confirms FDA feedback supports WVE-006 registrational pathway for AATD
dow_jonesimportance 0.40trust 0.80Wave Life Sciences Ltd. +0.50U.S. Food and Drug Administration +0.40WVE-006 +0.50+1 entities
2026-10-01 11:46:56 UTC#398254duplicateconfirmednews
Wave Life Sciences confirms FDA support for WVE-006 registrational trial pathway in AATD
reutersimportance 0.40trust 0.90Wave Life Sciences Ltd. +0.60WVE-006 +0.60U.S. Food and Drug Administration +0.50
2026-10-01 11:30:00 UTC#398207duplicateconfirmednews
Wave Life Sciences secures FDA agreement for single 2-year registrational trial of WVE-006 in AATD
tradingviewimportance 0.50trust 0.70Wave Life Sciences Ltd. +0.70U.S. Food and Drug Administration +0.60WVE-006 +0.70+1 entities
2026-10-01 11:30:00 UTC#398204newconfirmedpress release
Wave Life Sciences gains FDA alignment on WVE-006 registrational trial pathway for AATD
globenewswireimportance 0.70trust 1.00Wave Life Sciences Ltd. +0.60U.S. Food and Drug Administration +0.50WVE-006 +0.60+1 entities
2026-09-30 12:18:53 UTC#391304duplicateconfirmednews
Wave Life Sciences to receive $12M milestone payment following GSK's selection of liver candidate
2026-09-30 11:32:27 UTC#390967newconfirmednews
Wave Life Sciences to receive $12M milestone as GSK selects siRNA program for further development
2026-09-23 12:28:00 UTC#355338newconfirmednews
JPMorgan downgrades Wave Life Sciences (WVE) to Neutral from Overweight
2026-09-10 14:37:38 UTC#292964newconfirmednews
WAVE Life Sciences advances AATD and PNPLA3 RNA editing programs toward pivotal trials; Inhibin E data due 2026
2026-08-11 19:23:55 UTC#160786newconfirmednews
Wave Life Sciences outlines upcoming clinical and regulatory milestones for WVE-007 and AATD programs
quartrimportance 0.40trust 0.50Wave Life Sciences Ltd. +0.30WVE-007 +0.30Alpha-1 Antitrypsin Deficiency +0.30
2026-07-31 23:20:17 UTC#112060updateconfirmednews